DRC Ebola outbreak reaches 5,290 cases as vaccine protection remains uncertain

The Democratic Republic of Congo is facing its largest and deadliest Ebola outbreak on record. As of 20 August 2026, authorities had reported 5,290 confirmed Bundibugyo virus cases and 2,516 deaths, a confirmed-case fatality ratio of roughly 48%. 1 The World Health Organization has described the outbreak as being in a phase of “intense transmission” and expanding faster than any previous Ebola outbreak in the country. 13

The immediate challenge is not simply the virus’s high fatality rate. The outbreak is being driven by a strain for which no licensed vaccine or specific treatment exists, while insecurity, population movement and a difficult humanitarian environment are making surveillance and containment harder. 8

Why this outbreak is moving so quickly

The outbreak is caused by Bundibugyo ebolavirus, a different species from Zaire ebolavirus, the strain targeted by the licensed Ervebo vaccine. That distinction matters: vaccines and treatments developed for one Ebola species cannot automatically be assumed to work against another.

WHO says the outbreak is occurring in a remote and densely populated setting affected by humanitarian crisis, insecurity and substantial population and trade movement. Those conditions complicate case detection, contact tracing, isolation, clinical care and other standard response measures. 8

The scale is also changing rapidly. WHO reported 4,665 confirmed cases and 2,184 deaths as of 12 August, while the European Centre for Disease Prevention and Control recorded 5,290 confirmed cases and 2,516 deaths using data through 19 August. 113 The figures reflect different reporting cutoffs rather than a contradiction in the underlying trend.

What the 70,000 Ervebo doses can—and cannot—do

The International Coordinating Group on Vaccine Provision has allocated 70,000 doses of Merck’s Ervebo from the global Ebola vaccine stockpile. The first shipment—16,250 doses—arrived in Kinshasa on 22 August, with additional doses expected. 2310

The planned allocation gives the shipment two purposes:

• 50,000 doses are intended for frontline workers and communities involved in the response.
• 20,000 doses are intended for a Phase 3 clinical trial examining whether Ervebo provides protection against Bundibugyo virus. 56

Ervebo is licensed for Zaire ebolavirus, not Bundibugyo. Although the viruses are related, WHO has stressed that it remains unknown whether Ervebo will protect people against the strain circulating in the DRC. Its effectiveness against Bundibugyo has not been established in humans. 516

That makes the deployment both a public-health intervention and an urgent scientific test. Vaccinating frontline workers could reduce risk if the vaccine offers cross-protection, while the trial could generate evidence that is currently unavailable. But the trial will not produce an immediate answer, and early clinical data cannot instantly change transmission dynamics during an active outbreak.

The race to develop a Bundibugyo-specific vaccine

Two candidates designed specifically for Bundibugyo have entered first-in-human testing.

Oxford’s ChAdOx1 BDBV candidate

The University of Oxford launched the BD-Ebov Phase 1 trial in July. It is testing the safety and immune response generated by ChAdOx1 BDBV in 50 healthy adults aged 18 to 55. 3336

A Phase 1 study is an early safety and immune-response test. It is not designed to demonstrate that a vaccine stops transmission in an outbreak population. Larger studies would be needed before the candidate could become an established countermeasure.

Moderna’s mRNA-1469 candidate

Moderna began a Phase 1 trial in Canada in early August. The study is expected to enroll about 80 healthy adults and will assess safety, tolerability and immune responses to the company’s mRNA-1469 candidate. 3442

Both programs are important because they target the strain actually driving the DRC outbreak. However, they remain investigational. The candidates must still produce satisfactory early safety and immune-response data before they can advance to larger studies or potential emergency use. 3334

Why containment measures are under pressure

Isolation, contact tracing, surveillance, safe burials and clinical preparedness remain central to the response. WHO says it is supporting the DRC and Uganda in strengthening those measures. 8

The problem is that response capacity is being stretched across a fast-growing outbreak and a difficult operating environment. More cases mean more contacts to identify, more patients requiring isolation and treatment, and greater logistical demands on already limited teams. In that context, conventional measures remain necessary but may not be sufficient on their own to slow transmission quickly.

The central near-term question is whether the response can contain transmission before a proven Bundibugyo-specific vaccine or treatment becomes available. Ervebo may provide some cross-protection, but that remains an open question; the Oxford and Moderna candidates are further from deployment even though they are better matched to the strain.

Canada’s quarantine policy and the humanitarian response

Canada has imposed temporary border measures affecting people who have been in the DRC, Uganda or South Sudan during the previous 21 days. Canadian citizens and permanent residents who have been in the DRC are subject to a mandatory 21-day quarantine on arrival, while foreign nationals who have recently been in the DRC are barred from entering, subject to the rules and exemptions in force. The measures are scheduled to expire at 23:59 EDT on 29 August 2026. 192224

The policy has drawn criticism from humanitarian organizations and aid workers who say it can make deployment more difficult. Reporting from Toronto CityNews said at least 11 Canadians with MSF, also known as Doctors Without Borders, had cancelled assignments because of the quarantine requirement as of 20 August. 17

Canada has also faced criticism over the scale of its financial response. The Globe and Mail reported that Ottawa had announced an $8 million response, compared with more than $110 million contributed during the 2014 West Africa Ebola epidemic. 18 These figures are part of an ongoing political and humanitarian dispute, rather than a measure of the effectiveness of Canada’s public-health controls.

Canada’s own risk assessment described the risk of Bundibugyo virus importation as low and said onward transmission after an imported case would be expected to be very limited. 26 That assessment helps explain why critics question whether broad restrictions could impose costs on the specialist workforce needed at the outbreak’s source, while the government reviews the measures and the latest evidence.

What to watch next

The outbreak’s trajectory will depend on several developments:

1. Whether Ervebo shows cross-protection. The 20,000-dose Phase 3 study is intended to provide evidence, but results will not be immediate. 56
2. Whether Oxford’s and Moderna’s candidates pass early testing. Both are still in Phase 1, focused primarily on safety and immune response. 3334
3. Whether surveillance and contact tracing can keep pace. WHO has identified insecurity, mobility and the humanitarian setting as major operational challenges. 8
4. Whether international support reaches response teams quickly enough. Vaccine doses alone cannot replace case detection, isolation, treatment capacity and trained personnel.

For now, the defining uncertainty is the gap between what is available and what is proven: Ervebo can be deployed immediately but was designed for another Ebola species, while strain-matched vaccines are entering human testing but are not yet established tools for outbreak control.